This article discusses prazosin hydrochloride's capacity to decrease venous return directly, thereby indirectly decreasing afterload and cardiac mechanical work. Aspects of the pharmacology, biochemistry, biopharmaceutics, adverse effects and results of clinical studies with prazosin are included, as well as therapeutic use dosage and cost information.
Get full access to this article
View all access options for this article.
References
1.
Personal Communication: Pfizer, Inc., New York, N.Y.
2.
HessH. J.: Prazosin: Biochemistry and Structure-Activity Studies, Post. Grad. Med. Symp.58: 9–17 (Nov.) 1975.
3.
AwanN. A.MillerR. R.: Efficacy of Ambulatory Systemic Vasodilator Therapy with Oral Prazosin in Chronic Refractory Heart Failure, Circulation56: 346–354 (Sept.) 1977.
4.
MillerR. R.: Sustained Reduction of Cardiac Impedence and Preload in Congestive Heart Failure with Antihypertensive Vasodilator Prazosin, N. Engl. J. Med.297: 303–307 (Aug.) 1977.
5.
ConstantineJ. W.: Analysis of Hypotensive Action of Prazosin, Post. Grad. Med. Symp.58: 18–35 (Nov.) 1975.
6.
MehtaJ.IaconaM.FeldmanR. L.PepineC. J.ContiC. R.: Comparative Hemodynamic Effects of Intravenous Nitroprusside and Oral Prazosin in Refractory Heart Failure, Am. J. Cardiol.41: 925–930 (May) 1978.
7.
AwanN. A.MillerR. R.MasonD. T.: Comparison of Effects of Nitroprusside and Prazosin on Left Ventricular Function and Peripheral Circulation in Chronic Refractory Congestive Heart Failure, Circulation57: 152–159 (Jan.) 1978.
8.
AwanN. A.: Clinical Pharmacology and Therapeutic Application of Prazosin in Acute and Chronic Refractory Congestive Heart Failure, Am. J. Med.65: 146–154 (July) 1978.
9.
ColinJ. N.: Vasodilator Therapy for Heart Failure: The Influence of Impedence on Left Ventricular Performance, Circulation48: 5–8, 1973.
10.
HobbsD. C.TwoneyT. M.: Pharmacokinetics of Prazosin in Man, Unpublished Data, 1977.
11.
WoodA. J.LeeD. R.: Effects of Prazosin on Sodium and Body Fluids, Proc. Univ. Otago Med. School52: 12, 1974.
12.
RougierM.LahonH. J.: Prazosin: A New Anti-hypertension Agent, Br. J. Clin. Pract.28: 280, 1974.
13.
Red Book, Medical Economics Co., Oradell, N.J., 1978.
14.
GabrielR.: Adverse Reactions to Prazosin, Brit. Med. J.3: 593, 1975.
15.
RosendorffC.: Prazosin: Severe Side Effects are Dose Dependent, Br. Med. J.3: 508, 1976.
SimpsonF. O.BolliP.: Use of Prazosin at the Dunedin Hypertension Clinic, Special Suppl.Med. J. Aust. August, 1977.
18.
ChatterjeeK.: Long Term Outpatient Vasodilator Therapy of Congestive Heart Failure, Am. J. Med.65: 134–145 (July) 1978.
19.
MasonD. T.: Afterload Reduction and Cardiac Performance: Physiologic Basis of Systemic Vasodilators as a New Approach in Treatment of Congestive Heart Failure, Am. J. Med.65: 106–125 (July) 1978.
20.
BraunwaldE.: Vasodilator Therapy, A Physiologic Approach to the Treatment of Heart Failure, N. Engl. J. Med.297: 331–332 (Aug.) 1977.
21.
CohnJ. N.FranciosaJ. A.: Vasodilator Therapy of Cardiac Failure (Second Part), N. Engl. J. Med.297: 254–258 (Aug.) 1977.
22.
MehtaJ.: Vasodilators in the Treatment of Heart Failure, J. Am. Med. Assoc.238: 2334–2336 (Dec.) 1977.
23.
AronowW. S.DanahyD. T.: Efficacy of Trimazosin and Prazosin Therapy on Cardiac and Exercise Performance in Outpatients with Chronic Congestive Heart Failure, Am. J. Med.65: 155–160 (July) 1978.
24.
BrogdenR. N.HeelR. C.SpeightT. M.AveryG. S.: Prazosin: A Review of Its Pharmacological Properties and Therapeutic Efficacy in Hypertension, Drugs14: 163–197, 1977.
